Business Wire

BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report

22.1.2025 10:00:00 EET | Business Wire | Press release

Share

BON CHARGE, a global leader in premium wellness technology, today announces the release of its inaugural Global Red Light Therapy Trend Report, showcasing how red light therapy is fast becoming a cornerstone of modern wellness routines. Based on a global survey of 7,000 adults across the U.S., UK, UAE, and Australia, the report highlights the rising adoption of red light therapy, particularly among younger consumers, with the UAE leading with seven in ten adults actively using red light therapy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122177591/en/

BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report (Photo: Business Wire)

Coinciding with the release, BON CHARGE debuts its brand refresh, including a redesigned website. This emphasizes BON CHARGE’s mission to simplify wellness by offering the world’s widest range of wellness products on a single, easy-to-access platform, empowering individuals to prioritize their self-care with science-backed technology solutions.

“As consumers become increasingly interested in their overall wellness, they are searching for accessible tools that offer multiple benefits, making red light therapy a game-changer,” said Katie Mant, Co-Founder of BON CHARGE. “Our research underscores its impact on key areas like skin appearance, sleep, and recovery, showcasing its role in shaping the future of proactive wellness worldwide.”

Red Light Therapy: A Global Trend in Wellness

The BON CHARGE Global Red Light Therapy Trend Report provides key insights into how this emerging technology is reshaping global wellness routines:

  • UAE Leading the Way: Red light therapy has gained remarkable traction in the UAE, where 70% of adults report using it—far exceeding adoption rates in other markets. Nearly a third (30%) use it monthly, underscoring its popularity as a regular wellness practice.
  • Younger Generations Drive Adoption: Across all surveyed markets, adults aged 18-34 are the most engaged users of red light therapy, with standout adoption rates of 77% in the UAE, 53% in the U.S. and Australia, and 46% in the UK.
  • A Recent Addition to Wellness Routines: Red light therapy is still a relatively new addition for many users, with two-thirds globally reporting they started in the past two years. Younger adults (18-34) are driving this trend, with 73% of users in the UK, 70% in the UAE and 71% in the U.S. and Australia having adopted the practice recently.
  • Top Device of Choice: Red light face masks lead globally as the most popular device, chosen by around a third of users (35% in the UAE, 34% in Australia, 36% in the UK and 27% in the U.S.). Note: Preferences vary by region with devices to soothe joint stiffness taking the lead in the UK and U.S. (38% and 30%, respectively).

Regional Insights Reflect Diverse Motivations

Red light therapy is a growing phenomenon. While muscle and joint relaxation is the top reason for use globally, regional nuances reveal additional motivations behind its widespread appeal:

  • United Arab Emirates: The UAE sets the pace for global adoption with nearly 70% of adults engaged with red light therapy. A greater understanding of red light therapy and professional endorsements drive this trend, with 37% of users recommended by a skin specialist.
  • Australia: Australians cite sleep improvement and skincare benefits as key reasons for use, after muscle and joint relaxation, and well over half (61%) have adopted red light therapy within the past two years.
  • United States: Adoption is stronger among men than women in the United States, with nearly 40% reporting usage. Improved sleep and mood are cited as key motivators (28% and 24%, respectively) by users, highlighting the growing focus on recovery and mental well-being.
  • United Kingdom: While adoption lags behind other markets, red light therapy is rapidly gaining traction among younger adults, with 73% of users aged 18-34 starting in the last two years. With lead motivation for use being skincare benefits, following muscle and joint relaxation.

“This report reflects a global movement toward proactive wellness,” said Andy Mant, Co-Founder of BON CHARGE. “Red light therapy’s rapid adoption, particularly among younger generations, signals a significant shift. As science continues to validate its benefits, we believe it will become as essential to wellness as nutrition and fitness.”

Explore the Full Report and Press Kit
Access the BON CHARGE Global Red Light Therapy Global Trend Report and explore key findings, visual assets, and additional resources in our digital press kit. Visit boncharge.com to download the report and learn more about BON CHARGE’s pioneering wellness solutions.

Notes to Editors
Research of 7,000 adults across the UK, USA, UAE, and Australia by Opinium Research in December 2024.

About BON CHARGE
Founded in 2017 by Katie and Andy Mant, BON CHARGE is setting new standards in simplifying wellness by offering the widest range of science-backed technology solutions to help individuals navigate their wellness journeys. The brand celebrates wellness as a continuous journey, honoring individuality and inspiring growth through community and shared knowledge. From sleep and recovery to beauty and mental well-being, BON CHARGE is a trusted partner in proactive self-care. Headquartered in Perth, Australia, every product is rooted in rigorous scientific research and designed to help individuals in achieving their wellness goals. For more information, visit boncharge.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250122177591/en/

Contacts

Press Contact
Jack Taylor PR
boncharge@jacktaylorpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release

Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear

Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI

SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0

NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release

NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and

Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release

In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye